A Perspective of Immunotherapy for Prostate Cancer

Recent advances in immuno-oncology and its application to urological cancers

Oncolytic virotherapy for urological cancers

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer

A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report

Response of blood flow to hyperthermia in human prostate tumors: Opportunities for enhanced radiation effect and drug delivery.